NCT02922777View on ClinicalTrials.gov

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 6, 2023

Study Completion Date

April 4, 2023

Conditions
Non-Small Cell Lung Carcinoma
Interventions
DRUG

BGB324

75 mg/m2 every 21 days

DRUG

Docetaxel

75 mg/m2 given IV every 21 days

Trial Locations (2)

75063

University of Texas Southwestern Medical Center, Dallas

79410

Covenant Health Systems/Joe Arrington Cancer Treatment and Research Center, Lubbock

Sponsors

Collaborators (1)

BerGenBio ASA
All Listed Sponsors
collaborator

Texas Tech University Health Sciences Center

OTHER

collaborator

BerGenBio ASA

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT02922777 - Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter